MX2020007948A - Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. - Google Patents

Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.

Info

Publication number
MX2020007948A
MX2020007948A MX2020007948A MX2020007948A MX2020007948A MX 2020007948 A MX2020007948 A MX 2020007948A MX 2020007948 A MX2020007948 A MX 2020007948A MX 2020007948 A MX2020007948 A MX 2020007948A MX 2020007948 A MX2020007948 A MX 2020007948A
Authority
MX
Mexico
Prior art keywords
intraocular
vascular permeability
neovascularization
preventing
activity
Prior art date
Application number
MX2020007948A
Other languages
English (en)
Inventor
Rie Yamamoto
Tomohiro Aoki
Hideaki Hara
Shuh Narumiya
Ichiro Aramori
Original Assignee
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto filed Critical Univ Kyoto
Publication of MX2020007948A publication Critical patent/MX2020007948A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona un producto farmacéutico para prevenir o tratar una enfermedad oftálmica asociada con la neovascularización intraocular y/o el aumento de la permeabilidad vascular intraocular. Los inventores de la presente invención han realizado investigaciones sobre un producto farmacéutico para prevenir o tratar una enfermedad oftálmica asociada con la neovascularización intraocular y/o el aumento de la permeabilidad vascular intraocular, y han confirmado que un agonista selectivo del receptor S1P que tiene actividad agonista en un receptor S1P1 tiene una acción reductora de la neovascularización intraocular y una acción reductora de la permeabilidad vascular intraocular, completando así la presente invención. Un compuesto o una sal farmacéuticamente aceptable del mismo de la presente invención, que sirve como el agonista selectivo del receptor S1P que tiene actividad agonista en el receptor S1P1, tiene una acción reductora de la neovascularización intraocular y una acción reductora de la permeabilidad vascular intraocular, y puede usarse como un agente preventivo y/o terapéutico para, por ejemplo, la degeneración macular exudativa relacionada con la edad, retinopatía diabética, edema macular diabético, neovascularización coroidea de la miopía, oclusión arterial retiniana, oclusión venosa retiniana o glaucoma neovascular.
MX2020007948A 2018-02-02 2019-02-01 Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. MX2020007948A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018016911 2018-02-02
PCT/JP2019/003573 WO2019151470A1 (ja) 2018-02-02 2019-02-01 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬

Publications (1)

Publication Number Publication Date
MX2020007948A true MX2020007948A (es) 2020-12-10

Family

ID=67479734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007948A MX2020007948A (es) 2018-02-02 2019-02-01 Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular.

Country Status (17)

Country Link
US (1) US20210113529A1 (es)
EP (1) EP3747471A4 (es)
JP (1) JPWO2019151470A1 (es)
KR (1) KR20200116953A (es)
CN (1) CN111683682A (es)
AU (1) AU2019214265A1 (es)
BR (1) BR112020015567A2 (es)
CA (1) CA3089952A1 (es)
IL (1) IL275603A (es)
JO (1) JOP20200186A1 (es)
MA (1) MA53098A (es)
MX (1) MX2020007948A (es)
PH (1) PH12020551015A1 (es)
RU (1) RU2020128700A (es)
SG (1) SG11202006255UA (es)
WO (1) WO2019151470A1 (es)
ZA (1) ZA202004327B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021148439A1 (en) * 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stimulating cerebrovascular function
WO2021163355A1 (en) * 2020-02-11 2021-08-19 Arena Pharmaceuticals, Inc. Formulations and methods of treating conditions related to the s1p1 receptor
EP4164605A4 (en) * 2020-06-11 2024-06-19 The Trustees of Columbia University in the City of New York METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH FINGOLIMOD, A SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR AND DERIVATIVES THEREOF
CN113082031A (zh) * 2021-03-09 2021-07-09 温州医科大学附属眼视光医院 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用
CN119776509A (zh) * 2023-10-08 2025-04-08 华东师范大学 Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1643983T3 (pl) * 2003-06-24 2010-10-29 Univ Connecticut Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
RU2409570C2 (ru) 2006-02-03 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. Производные триазола
CN101415687B (zh) 2006-02-06 2012-02-08 大正制药株式会社 鞘氨醇-1-磷酸结合抑制物质
PL2003132T3 (pl) 2006-04-03 2014-10-31 Astellas Pharma Inc Pochodne oksadiazolu jako agoniści S1P1
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
US20100111963A1 (en) 2006-11-10 2010-05-06 Genentech, Inc. Method for treating age-related macular degeneration
EP2014653A1 (en) * 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
US8048898B2 (en) 2007-08-01 2011-11-01 Taisho Pharmaceutical Co., Ltd Inhibitor of binding of S1P1
MX2011005954A (es) 2008-12-05 2011-10-11 Astellas Pharma Inc Compuesto de 2h-cromeno y su derivado.
EP2491023B1 (en) 2009-10-23 2014-12-31 Allergan, Inc. Coumarin compounds as receptor modulators with therapeutic utility
MX2012006028A (es) 2009-11-24 2012-06-19 Allergan Inc Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
ES2468827T3 (es) 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
US8273776B2 (en) 2010-04-16 2012-09-25 Allergan, Inc Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators
CN103402986A (zh) 2010-11-24 2013-11-20 阿勒根公司 S1p受体的调节剂
AU2011332196A1 (en) 2010-11-24 2013-07-11 Allergan, Inc. Indole derivatives as modulators of S1P receptors
JP2014508106A (ja) 2010-12-03 2014-04-03 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸−１受容体モジュレーターとしてのアルキンおよびアルケン誘導体
EP2671589A4 (en) 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
EP2697195A1 (en) 2011-04-14 2014-02-19 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
JP2014518554A (ja) 2011-04-18 2014-07-31 アラーガン インコーポレイテッド スフィンゴシン−１リン酸受容体調節剤としての置換二環式メチルアミン誘導体
US9000016B2 (en) 2012-11-05 2015-04-07 Allergan, Inc. 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators
US8735433B1 (en) 2012-11-14 2014-05-27 Allergan, Inc. Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators
US20140235613A1 (en) 2013-02-20 2014-08-21 Allergan, Inc. Substituted diaryl azetidine derivatives as sphingosine receptor modulators
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
JP2018016911A (ja) 2016-07-28 2018-02-01 村田機械株式会社 解析装置

Also Published As

Publication number Publication date
RU2020128700A3 (es) 2022-03-02
PH12020551015A1 (en) 2021-09-06
JPWO2019151470A1 (ja) 2021-02-25
EP3747471A4 (en) 2021-10-27
BR112020015567A2 (pt) 2021-02-02
ZA202004327B (en) 2022-01-26
WO2019151470A1 (ja) 2019-08-08
JOP20200186A1 (ar) 2020-07-29
EP3747471A1 (en) 2020-12-09
IL275603A (en) 2020-08-31
RU2020128700A (ru) 2022-03-02
CN111683682A (zh) 2020-09-18
US20210113529A1 (en) 2021-04-22
AU2019214265A1 (en) 2020-07-23
CA3089952A1 (en) 2019-08-08
SG11202006255UA (en) 2020-07-29
KR20200116953A (ko) 2020-10-13
MA53098A (fr) 2021-05-12

Similar Documents

Publication Publication Date Title
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
JP2015528454A5 (es)
EP4360709A3 (en) Use of a vegf antagonist to treat angiogenic eye disorders
MX2022001433A (es) Tratamiento personalizado de enfermedades oftalmologicas.
JP2008538215A5 (es)
RU2009145939A (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
AU2017261303A1 (en) Ophthalmic compositions
Cole et al. Bilateral acute angle-closure glaucoma in a migraine patient receiving topiramate: a case report
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
Eibenberger et al. Effects of intravitreal dexamethasone implants on retinal oxygen saturation, vessel diameter, and retrobulbar blood flow velocity in ME secondary to RVO
Sumnicht et al. The role of oral steroids in the treatment of photodynamic therapy-associated exudative maculopathy, a case report and review of the literature
NZ594728A (en) Use of deferiprone for treatment and prevention of iron-related eye disorders
JP2013513606A5 (es)
HRP20192256T1 (hr) Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta
Cho et al. Reversal of early central retinal vein occlusion by alleviating optic nerve edema with an intravitreal dexamethasone implant
Wasik et al. Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma
Shaheen Comparison of ParsPlanaVitrectomy WithAnti VEGF Injection As A primary Management ForDiabetic Macular Edema
Casati Increased introcular pressure, retinal and vitreous haemorrhage leading to decreased visual acuity caused by device malfunction: case report
Yamashita et al. A case of Coats' disease with visual recovery from no light perception vision after vitrectomy
Semeraro Acute uveitis following intravitreal administration in elderly patients: 4 case reports
Abdel Kader et al. Effects of Intravitreal Injection of Ranibizumab on Intraocular Pressure
Orssaud Urrets-Zavalia syndrome as a complication of ocular hypotonia and bilateral anterior uveitis: case report
Iqbal et al. Assessment of ocular and systemic complcations after intravitreal bevacizumab injection for macular edema in branch retinal vein occlusion
Matsubara Aflibercept/ranibizumab